Here we intend to dwell on a further element which, starting from the project areas, has the potential to open up a broader front for reflection on medicine as an object. The problematic opening we propose concerns the object—and the medicine as object—in its device nature. ...
Occasionally, it can cause allergic reactions and thrombocytopenia often occurs in the first 5 to 9 days of medication, so the platelet count should be monitored regularly within 1 month after starting treatment. Occasionally one-time hair loss and diarrhea. Can still cause...
The EMA starts the evaluation procedure of the MAA at the monthly starting date published on the EMA website once the application is validated. The EMA ensures that the evaluation is finalized within 210 days (excluding any clock-stops for the applicant to provide a response to questions raised...
To improve healthcare outcomes and ensure the financial protection of the population, starting from 2017, the Government of Ukraine implemented a range of healthcare reforms.Global Pharmaceutical Policydoi:10.1007/978-981-15-2724-1_9Grintsova Olga...
As such, none of the patients were clearly ‘rejecters’ or ‘active modifiers’ of their medicines as described in the medicines resistance model, so the discussion now considers whether their acceptance of medicines aligns with the ‘medicines-resistance’ model, starting with ‘passive acceptors’...
Randomized placebo‐controlled, single blind trial of holy basil leaves in patients with noninsulin‐dependent diabetes mellitus. International journal of clinical pharmacology and therapeutics 1996;34(9):406‐9. PubMed Google Scholar Agrawal 2002 {published data only} Agrawal RP, Sharma A, ...
For patients expected to be on prolonged treatment or who take proton pump inhibitors with digoxin or medicinal products that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting proton pump...
Frontier Medicines is a clinical stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically-defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics powered drug discovery engine, the Frontier™ Platform, levera...
discovery moved toward rational design and the screening of ever-larger libraries of compounds. But uncertainty and time remain limitations today, largely because of the difficulty in finding good starting matter from the estimated 1060possible drug-like compounds1. AI-enabled approaches are putting mor...
On the basis of these public screening results, a library of 400 unique compounds with blood-stage antimalarial activity was created. These compounds have been resynthesized and this 'malaria box' of potential chemical starting points can be obtained from the Medicines for Malaria Venture (MMV). ...